

1. Record Nr.	UNINA9910253942303321
Autore	Trottet Lionel
Titolo	Dermal Drug Selection and Development : An Industrial Perspective / / by Lionel Trottet, Howard Maibach, MD
Pubbl/distr/stampa	Cham : , : Springer International Publishing : , : Imprint : Springer, , 2017
ISBN	3-319-59504-0
Edizione	[1st ed. 2017.]
Descrizione fisica	1 online resource (154 pages)
Disciplina	615.19
Soggetti	Pharmaceutical chemistry Dermatology Pharmaceutics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Introduction -- Choosing the topical drug candidate -- Key factors affecting the efficacy of a topical drug candidate -- Topical vs. Oral/systemic Drug discovery -- Assessing drug concentration in skin -- Assessing Topical efficacy -- Assessing the therapeutic index -- Topical vehicle selection -- Topical drug development strategies -- Topical drug candidate selection criteria and cascade -- Selecting a dermal drug candidate -- Conclusions and perspectives.
Sommario/riassunto	The authors show how the pharmaceutical industry faces the development of dermal drugs and provide the only book of its kind that describes how the industry develops and selects dermal drugs, complete with the challenges and opportunities of the field. Delivery of drugs through the skin has been an attractive and challenging area for research, and advances in modern technologies have resulted in a larger number of drugs being delivered transdermally, including conventional hydrophobic small molecule drugs, hydrophilic drugs and macromolecules. Offering the perspective from the industrial side of selection and development of drugs, the primary audience is geared towards the pharmaceutical industry but can also offer valuable information to clinicians, compounding pharmacists, and similarly pharmacy students. Dermal Drug Selection and Development covers the scientific gaps that exist in terms of dermal pharmacokinetics and the

resulting uncertainty by clinicians when choosing a drug candidate.

---